¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"Exposure to uncontrolled fire in building or structure"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 9 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • occupational exposure
    Á÷¾÷³ëÃâ
  • prolonged exposure
    Àå±â³ëÃâ
  • public exposure
    °øÁßÇÇÆø, °øÁß³ëÃâ
  • radiation exposure
    ¹æ»ç¼±³ëÃâ
  • short term exposure
    ´Ü±â³ëÃâ
  • subanesthetic exposure
    Áظ¶Ãë³ëÃâ
  • sun exposure
    Àϱ¤³ëÃâ
  • permissible exposure limit
    Çã¿ëÇÇÆøÇѰè
  • permissible radiation exposure level
    Çã¿ë¹æ»ç¼±ÇÇÆø¼±·®
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • internal exposure
    ü³»ÇÇÆø
  • nuclear radiation exposure
  • occupational exposure
    Á÷¾÷¼º ³ëÃâ.
  • occupational exposure
    Á÷¾÷ÇÇÆø
  • permissible radiation exposure level
    Çã¿ë¹æ»ç¼±ÇÇÆø¼±·®
  • prolonged exposure
    Àå±â³ëÃâ.
  • public exposure
    °øÁßÇÇÆø
  • short term exposure
    ´Ü±â³ëÃâ.
  • subanesthetic exposure
    ¸¶Ã뿪ÇÏÇÇÆø.
  • sun exposure
    Àϱ¤³ëÃâ
  • water-air exposure rate, WAR
    ¼ö°øÁßÁ¶»ç¼±·®ºñ, ¹°-°ø±âÁßÁ¶»ç¼±·®ºñ
  • alveolar structure
    Æ÷»ó±¸Á¶(¡­Ï°ðã).
  • alveolar structure
    ÆóÆ÷±¸Á¶(¡­Ï°ðã)
  • antibody structure
    Ç×ü±¸Á¶(¡­Ï°ðã).
  • antigenic structure
    Ç׿ø±¸Á¶(¡­Ï°ðã).
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 3
EXELFS extended electron-loss line fine structure
hfs hyperfine structure
LFS lateral facet syndrome; Li-Fraumeni syndrome; limbic forebrain structure; liver function series
MTS Medicare transaction system; magnetization transfer contrast; methotrexate; multicellular tumor sphe...
QSAR quantitative structure-activity relationship
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 3
SCID Structure Clinical Interview for DSM-III-R
SFM Structure-from-motion
3-D-QSAR Three-dimensional quantitative structure-activity relationship
XAFS X-Ray Absorption Fine Structure
XANES X-ray Absorption Near Edge Structure
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • chemical structure
    È­ÇÐ ±¸Á¶
  • cubic structure
    µî¹æ ±¸Á¶, ÀÔ¹æ ±¸Á¶
  • decidua structure
    Å»¶ô¸· ±¸Á¶
  • diencephalic structure
    °£³ú ±¸Á¶
  • domain structure
    ¿µ¿ª ±¸Á¶
  • electron structure of atom
    ¿øÀÚÀÇ ÀüÀÚ ±¸Á¶
  • encapsulated structure
    Çdz¶ ±¸Á¶
  • extracranial structure
    µÎ°³¿Ü ±¸Á¶¹°
  • locomotor structure
    ¿îµ¿ ±¸Á¶¹°
  • monoclinic structure
    ´Ü»ç ±¸Á¶
  • mosaic structure
    ¸ðÀÚÀÌÅ© ±¸Á¶
  • neurologic structure
    ½Å°æ ±¸Á¶
  • organomineral structure
    À¯±â ¹«±âÁú ±¸Á¶
  • other facial structure
    ´Ù¸¥ ¾È¸é ±¸Á¶¹°
  • peripheral structure
    ¸»ÃÊ Á¶Á÷
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
cointegrate structure A structure of DNA produced by the fusion of two replicons, one possessing a transposon.
(05 Mar 2000)
cruciform structure A structure, shaped like a cross, which can form during homologous recombination when inverted base-pair repeats pair with each other on the same strand of DNA instead of with homologous sections on a different strand of DNA.
(09 Oct 1997)
crystal structure <chemistry> The configuration in which atoms are arranged in a material. These arrangements have a direct effect on the physical properties of the material. These arrangements commonly take the form of cubes, rectangular solids, hexagonal solids. Etc.
(05 Aug 1998)
primary structure The covalent backbone of a macromolecule. The order of subunits in a biological polymer, such as amino acids in a polypeptide or nucleotides in a molecule of DNA or RNA.
(09 Oct 1997)
protein structure The amino acids and their manner of arrangement in constituting a protein. The four stages of protein structuring are primary (protein structure, primary see amino acid sequence), secondary (protein structure, secondary), tertiary (protein structure, tertiary), and quaternary (protein structure, quaternary see protein conformation).
(12 Dec 1998)
protein structure, secondary The stage in the development of protein structure in which regular hydrogen-bond interactions within contiguous stretches of polypeptide chain give rise to alpha helices and beta sheets. This is the first folding level of protein building.
(12 Dec 1998)
protein structure, tertiary The stage in the structural development of a protein in which combinations of alpha helices and beta sheets pack together to form compactly folded globular units named domains. Small proteins consist of only one domain but larger proteins contain a number of domains which are usually connected by open lengths of polypeptide chain. This stage is a combination of the second and third folding levels of protein building.
(12 Dec 1998)
secondary structure <molecular biology> Structures produced in polypeptide chains involving interactions between amino acids within the chain. Especially _ helical and _ pleated sheet structures. Also applies to the complex folding of nucleic acids as, for example: the clover leaf structure of tRNA.
(18 Nov 1997)
Holliday structure <molecular biology> A structure which occurs during homologous recombination between homologous chromosomes. While the two chromosomes are side by side, one strand of DNA on each chromosome is broken and then attached to the broken strand of DNA on the other chromosome. The crossover point, which is called the Holliday junction, is able to slide up and down between the two chromosomes, so that a little or a lot of DNA can ultimately be switched between them.
(09 Oct 1997)
soil structure The combination or arrangement of primary soil particles into secondary particles, units or peds.
(09 Oct 1997)
stem and loop structure <molecular biology> The structure of tRNAs is so termed because it has four base paired stems and three loops (not base paired), one of which contains the anticodon.
(18 Nov 1997)
structure <microscopy> The mode of construction of an animate or inanimate body or system from units such as atoms, ions, molecules, cells, crystals in a fluid, plastic, or solid state. Cf. Morphology.
(05 Aug 1998)
structure activity analysis Study in which systematic variation in the structure of a compound is correlated with its activity, in an attempt to determine the characteristics of the (receptor) site at which it acts.
(18 Nov 1997)
structure-activity relationship The relationship between the chemical structure of a compound and its biological or pharmacological activity. Compounds are often classed together because they have structural characteristics in common including shape, size, stereochemical arrangement, and distribution of functional groups. Other factors contributing to structure-activity relationship include chemical reactivity, electronic effects, resonance, and inductive effects.
(12 Dec 1998)
structure-functionalism The scientific tradition that stresses the relationship between aphysical structure and its function, for example: the related disciplinesof anatomy and physiology.
(09 Oct 1997)
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • fire-walking
    ºÒ °Ç³Ê±â
  • quick-fire
    ¼Ó»çÀÇ
  • Fire Service
    ¼Ò¹æ´ë
  • Great Fire
    (1666³âÀÇ)·±´ø ´ëÈ­Àç
  • Greek fire
    ±×¸®½º È­¾à(ÀûÇÔÀÇ È­°øµî¿¡ ¾²¿´À½)
  • beacon fire
    ½ÅÈ£ÀÇ È¶ºÒ
  • cease-fire
    (»ç°ÝÁßÁö)ÀÇ ±¸·É;Á¤Àü(¸í·É);ÈÞÀü
  • center-fire
    (ź¾àÅëÀÌ)±âÀúºÎ Áß¾Ó¿¡ ³ú°üÀÌ ÀÖ´Â
  • cross fire
    ½ÊÀÚÆ÷È­;(Áú¹®ÀÇ)ÀÏÁ¦ °ø¼¼;(¸»ÀÇ)°Ý·ÄÇÑ ÀÀ¼ö;Ç÷¹ÀÌÆ®ÀÇ °¢À» ÁÇ·Î °¡·ÎÁö¸£´Â Åõ±¸
  • crown fire
    (»êºÒÀÇ) ¼ö°üÈ­
  • curtain-fire
    ꏷ Æ÷È­(»ç°Ý);ꏷ
  • dead fire
    =ST.ELMO'S FIRE
  • death fire
    µµ±úºñºÒ(Á×À½ÀÇ Â¡Á¶)
  • electric fire
    (¿µ)Àü±â ¹é¿­ È÷ÅÍ
  • elf fire
    µµ±úºñ ºÒ
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 3
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 3
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 3
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 3
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 3
ÅëÇÕ°Ë»ö ¿Ï·á